Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.
Also called NCT04221217
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 120 participants
- Registry
-
NCT04221217
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT04221217. Randomized; no masking; primary purpose treatment. Start 2020-02-14 (actual); primary completion 2021-07-14 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia
- Condition
- Hypertriglyceridemia
- Intervention (Drug)
- Icosapent
- Lead sponsor
- Mochida Pharmaceutical Company, Ltd.
Record details
- Record id
cardio:ct-nct04221217- Content hash
f8d51aea8ea28a3576761638d2535662566eb54d5e076d9762f54ea161e8eeaf